K Pharma,Inc.
Research K Pharma,Inc. (4896.T) on Bullrun: market cap JPY 8.51B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4896.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 8.51B
- Financial periodFY2025
- RevenueJPY 0
- Net income-JPY 993.23M
- Free cash flow-JPY 929.19M
Valuation Snapshot
latest market cap is JPY 8.51B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | JPY 0 | -JPY 993.23M | -JPY 929.19M | n/a | -85.59 | JPY 2.79B | JPY 1.50B | JPY 1.27B |
| FY2024 | JPY 0 | -JPY 846.46M | -JPY 998.21M | n/a | -72.94 | JPY 2.27B | JPY 0 | JPY 2.26B |
| FY2023 | JPY 1.00B | JPY 260.33M | JPY 444.62M | 91.0% | 23.07 | JPY 3.27B | n/a | JPY 3.10B |
| FY2022 | JPY 0 | -JPY 392.43M | -JPY 393.44M | n/a | -42.06 | JPY 1.34B | n/a | JPY 1.34B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 8.51B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About K Pharma,Inc.
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is headquartered in Minato, Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is K Pharma,Inc.'s market cap?
K Pharma,Inc.'s market capitalization is JPY 8.51B.
What does K Pharma,Inc. do?
K Pharma,Inc. engages in the research, development, manufacture, and sale of regenerative medicines and pharmaceutical products in Japan. It develops regenerative medicine products using disease-specific induced pluripotent stem (iPS) cell technology for spinal cord injuries and cerebral infarctions. The company was incorporated in 2016 and is headquartered in Minato, Japan.